Raloxifene
Back to searchMolecule Structure
Scientific Name
Raloxifene
Description of the Drug
Raloxifene is a selective estrogen receptor modulator that is used to prevent and treat osteoporosis and reduce the risk of invasive breast cancer in high-risk postmenopausal women.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB00481
http://www.drugbank.ca/drugs/DB00481
Brand Name(s)
Not Available
Company Owner(s)
Invagen Pharmaceuticals Inc, Watson Laboratories Inc, Eli Lilly And Co, Aurobindo Pharma Ltd, Amneal Pharmaceuticals, Glenmark Pharmaceuticals Ltd, Teva Pharmaceuticals Usa, Sciegen Pharmaceuticals Inc, Cadila Pharmaceuticals Ltd
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Estrogen receptor beta | SINGLE PROTEIN | MODULATOR | CHEMBL242 |
Clinical Trial(s)
Unichem Links
| Atlas | raloxifene | ||
| SureChEMBL | SCHEMBL6144 | ||
| PharmGKB | PA451221 | ||
| Human Metabolome Database | HMDB0014624 | ||
| DrugBank | DB00481 | ||
| PubChem: Thomson Pharma | 14834427 | ||
| PubChem | 5035 | ||
| Mcule | MCULE-4598311006 | ||
| LINCS | LSM-3425 | ||
| Nikkaji | J22.982B | ||
| PDBe | RAL | ||
| BindingDB | 19441 | ||
| EPA CompTox Dashboard | DTXSID3023550 | ||
| DrugCentral | 2351 | ||
| Brenda | 78064 | 4142 | |
| ChemicalBook | CB1290431 | ||
| Guide to Pharmacology | 2820 | ||
| rxnorm | RALOXIFENE HYDROCHLORIDE | EVISTA | RALOXIFENE |
| KEGG Ligand | C07228 | ||
| ChEBI | 8772 | ||
| ZINC | ZINC000000538275 |
